HESTERBIO

Hester Biosciences Limited

Hester Biosciences Limited (HESTERBIO) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

hester.in(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹2236.50
Market cap
1,907 Cr
Stock P/E
14.0
P/B
5.28
Dividend yield
0.3%
ROE (FY26)
15.1%
ROCE (FY26)
15.6%
Operating margin (FY26)
20.4%
Debt / equity (FY26)
0.52
OCF / EBITDA (FY26)
74.0%
OCF / EBITDA (3Y)
87.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Hester Biosciences makes vaccines and other biological health products for poultry, livestock and pets, selling mainly in India with operations in Africa and Nepal.

Company snapshot

80thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 59.7% of revenue

SegmentRevenue shareRevenuePBTAssets
Animal Healthcare
38.8%
25 Cr5 Cr218 Cr
Others—0 Cr0 Cr0.29 Cr
PetCare
1.5%
0.97 Cr-0.47 Cr3 Cr
Poultry Healthcare
59.7%
38 Cr5 Cr252 Cr

What we see

Positives
  • ✓Net margin of 17.3% — the business keeps a healthy share of every rupee it earns.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales70 Cr67 Cr79 Cr82 Cr84 Cr63 Cr82 Cr84 Cr71 Cr77 Cr100 Cr77 Cr
Operating expenses (approx.)57 Cr57 Cr63 Cr65 Cr65 Cr58 Cr63 Cr61 Cr59 Cr60 Cr66 Cr54 Cr
EBITDA13 Cr10 Cr16 Cr18 Cr19 Cr5 Cr19 Cr23 Cr12 Cr18 Cr34 Cr23 Cr
OPM %18.8%15.2%20.1%21.5%22.9%8.0%23.4%27.1%16.5%23.0%34.3%29.5%
Other income4 Cr0.99 Cr4 Cr1 Cr2 Cr8 Cr-7 Cr2 Cr10 Cr0.67 Cr-3 Cr2 Cr
Interest8 Cr2 Cr7 Cr5 Cr6 Cr-4 Cr6 Cr2 Cr2 Cr2 Cr5 Cr3 Cr
Depreciation4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr4 Cr6 Cr7 Cr
Profit before tax7 Cr6 Cr10 Cr11 Cr12 Cr13 Cr4 Cr20 Cr17 Cr14 Cr25 Cr102 Cr
Tax %40.2%37.3%35.2%29.3%29.3%14.6%58.9%14.3%15.9%31.2%34.0%4.9%
Net profit4 Cr4 Cr6 Cr7 Cr8 Cr11 Cr2 Cr17 Cr14 Cr9 Cr17 Cr97 Cr
EPS (₹)₹4.75₹4.73₹7.52₹8.80₹9.86₹13.41₹1.82₹20.33₹16.85₹10.94₹19.45₹113.71

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales125 Cr136 Cr178 Cr183 Cr214 Cr235 Cr266 Cr305 Cr311 Cr333 CrSign in free for the trailing twelve months
Operating expenses (approx.)84 Cr89 Cr110 Cr128 Cr146 Cr175 Cr215 Cr251 Cr250 Cr246 CrSign in free for the trailing twelve months
EBITDA41 Cr47 Cr68 Cr55 Cr69 Cr60 Cr51 Cr54 Cr61 Cr87 CrSign in free for the trailing twelve months
OPM %32.7%34.6%38.2%30.2%32.0%25.5%19.0%17.6%19.6%26.1%Sign in free for the trailing twelve months
Other income0.42 Cr3 Cr7 Cr6 Cr5 Cr14 Cr15 Cr11 Cr4 Cr10 CrSign in free for the trailing twelve months
Interest3 Cr4 Cr7 Cr7 Cr7 Cr4 Cr9 Cr20 Cr13 Cr11 CrSign in free for the trailing twelve months
Depreciation7 Cr10 Cr12 Cr13 Cr13 Cr17 Cr21 Cr17 Cr17 Cr19 CrSign in free for the trailing twelve months
Profit before tax31 Cr36 Cr57 Cr41 Cr50 Cr54 Cr40 Cr32 Cr40 Cr76 CrSign in free for the trailing twelve months
Tax %26.3%36.1%28.4%25.0%30.7%26.2%30.2%33.8%27.2%24.2%Sign in free for the trailing twelve months
Net profit23 Cr23 Cr41 Cr31 Cr35 Cr39 Cr28 Cr21 Cr29 Cr57 CrSign in free for the trailing twelve months
EPS (₹)₹26.79₹27.12₹47.84₹36.44₹40.79₹46.41₹32.96₹24.88₹33.89₹67.57Sign in free for the trailing twelve months
Dividend payout %————16.2%21.5%30.3%32.2%17.9%10.5%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr
Reserves113 Cr132 Cr169 Cr193 Cr220 Cr251 Cr271 Cr283 Cr306 Cr352 Cr
Borrowings63 Cr62 Cr81 Cr109 Cr105 Cr223 Cr268 Cr239 Cr208 Cr188 Cr
Other liabilities23 Cr37 Cr37 Cr69 Cr71 Cr72 Cr113 Cr120 Cr119 Cr122 Cr
Total liabilities213 Cr244 Cr299 Cr384 Cr411 Cr562 Cr670 Cr662 Cr653 Cr678 Cr
Fixed assets (net)102 Cr109 Cr144 Cr137 Cr132 Cr237 Cr259 Cr239 Cr233 Cr411 Cr
CWIP21 Cr32 Cr7 Cr74 Cr109 Cr80 Cr146 Cr168 Cr177 Cr9 Cr
Investments——0 Cr0 Cr—21 Cr25 Cr30 Cr34 Cr43 Cr
Loans & advances——0 Cr0.10 Cr—6 Cr6 Cr6 Cr6 Cr0.11 Cr
Inventories33 Cr40 Cr51 Cr64 Cr62 Cr75 Cr85 Cr76 Cr70 Cr73 Cr
Trade receivables27 Cr32 Cr32 Cr58 Cr49 Cr55 Cr80 Cr79 Cr73 Cr95 Cr
Cash & bank11 Cr12 Cr41 Cr23 Cr21 Cr25 Cr13 Cr13 Cr6 Cr3 Cr
Other assets19 Cr18 Cr25 Cr28 Cr37 Cr62 Cr56 Cr52 Cr55 Cr44 Cr
Total assets213 Cr244 Cr299 Cr384 Cr411 Cr562 Cr670 Cr662 Cr653 Cr678 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity35 Cr38 Cr47 Cr38 Cr58 Cr9 Cr24 Cr48 Cr65 Cr64 Cr
Cash from investing-30 Cr-26 Cr-22 Cr-74 Cr-38 Cr-117 Cr-77 Cr-23 Cr-19 Cr-3 Cr
Cash from financing2 Cr-11 Cr3 Cr19 Cr-18 Cr112 Cr42 Cr-26 Cr-52 Cr-49 Cr
Net cash flow6 Cr1 Cr28 Cr-18 Cr-2 Cr3 Cr-12 Cr-0.41 Cr-7 Cr-3 Cr
Free cash flow (OCF − Capex)5 Cr15 Cr24 Cr-35 Cr17 Cr-87 Cr-54 Cr24 Cr44 Cr46 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %18.2%19.4%24.2%15.4%16.7%11.7%8.9%9.5%9.8%15.6%
ROE %18.6%17.7%22.9%14.1%14.7%14.7%9.2%6.2%8.4%15.1%
Debtor days77866511684861099486104
Inventory days689639630795586452583508401374
Days payable154127108231264108206178167127
Cash conversion cycle612598586680405430486425319351
OCF / EBITDA %84.8%80.5%68.7%69.1%84.5%14.7%46.6%89.7%105.7%74.0%
OCF / EBITDA % (3 years)——76.5%72.1%74.5%57.1%50.5%49.0%82.4%87.8%
Debt / equity0.520.440.460.540.460.860.960.820.660.52
Current ratio2.101.802.931.942.632.011.532.031.561.37
Net debt / EBITDA1.261.050.591.55—3.305.044.223.312.14